文献速递眼底病与葡萄膜炎小儿眼科与斜弱视眼整形与眼眶

基于第8版美国癌症联合委员会病理分期的1411例视网膜母细胞瘤患者结局

Retinoblastoma Outcomes Based on the 8th Edition American Joint Committee on Cancer Pathological Classification in 1411 Patients.
PubMed 文献 · Ophthalmology · 2024-09-07

这项回顾性、多中心、跨洲协作研究纳入1411例视网膜母细胞瘤患者,按第8版AJCC病理分类评估结局。中位随访35个月,pT1至pT4的眶内复发、肿瘤相关转移和肿瘤相关死亡均随pT分期升高而增加(P<0.001)。多因素分析显示pT分类和辅助治疗是结局的独立预测因素,pT3和pT4患者接受辅助治疗与较低的眶内复发、转移和死亡风险相关。

要点

  • pT1至pT4的眶内复发率分别为1%、3%、4%、23%(P<0.001)。
  • pT1至pT4的肿瘤相关转移率分别为1%、3%、8%、43%(P<0.001)。
  • pT1至pT4的肿瘤相关死亡率分别为2%、4%、13%、59%(P<0.001)。

核心结论

  • 第8版AJCC病理分类可预测接受初次眼球摘除术的视网膜母细胞瘤患者的结局。
  • 在pT3和pT4类别中,辅助治疗与较低的眶内复发、肿瘤相关转移和肿瘤相关死亡风险相关。

研究设计与样本

  • 回顾性、多中心、跨洲协作研究,共纳入1411例患者。
  • 干预为初次眼球摘除术,伴或不伴辅助化疗或放疗。
  • 主要结局指标为眶内肿瘤复发、肿瘤相关转移和肿瘤相关死亡。

主要发现

  • 按第8版AJCC病理分类,645眼(46%)为pT1,164眼(11%)为pT2,493眼(35%)为pT3,109眼(8%)为pT4。
  • 平均随访38个月(中位35个月,范围<1至149个月),眶内肿瘤复发在pT1、pT2、pT3、pT4分别为8例(1%)、5例(3%)、22例(4%)、25例(23%)(P<0.001)。
  • 肿瘤相关转移在pT1、pT2、pT3、pT4分别为7例(1%)、5例(3%)、40例(8%)、46例(43%)(P<0.001)。
  • 肿瘤相关死亡在pT1、pT2、pT3、pT4分别为12例(2%)、7例(4%)、64例(13%)、64例(59%)(P<0.001)。
  • 多因素Cox比例风险分析显示pT分类和辅助治疗是结局的独立预测因素。

关键数值与推荐

  • 与pT1类别相比,pT3b(P=0.005)、pT3c(P<0.001)、pT3d(P<0.001)和pT4(P<0.001)的眶内复发风险更高。
  • 与pT1类别相比,pT2a(P=0.015)、pT3a(P<0.001)、pT3b(P<0.001)、pT3c(P<0.001)、pT3d(P<0.001)和pT4(P<0.001)的肿瘤相关转移风险更高。
  • 与pT1类别相比,pT2a(P=0.068)、pT2b(P=0.004)、pT3a(P<0.001)、pT3b(P<0.001)、pT3c(P<0.001)、pT3d(P<0.001)和pT4(P<0.001)的肿瘤相关死亡风险更高。
  • 与接受辅助治疗者相比,未接受辅助治疗者在pT3b(P=0.005)、pT3c(P=0.003)和pT4(P=0.002)类别的眶内肿瘤复发风险更高。
  • 与接受辅助治疗者相比,未接受辅助治疗者在pT3a(P=0.001)、pT3b(P=0.01)、pT3c(P=0.001)和pT4(P=0.007)类别的肿瘤相关转移风险更高。

临床怎么用

  • 第8版AJCC病理分类可用于预测接受初次眼球摘除术的视网膜母细胞瘤患者的结局。
  • 在pT3和pT4类别中,辅助治疗与较低的眶内复发、肿瘤相关转移和肿瘤相关死亡风险相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the outcomes of retinoblastoma (RB) based on the 8th edition of the American Joint Committee on Cancer (AJCC) pathological classification in a global cohort of patients. DESIGN: Retrospective, multicenter, intercontinental, collaborative study. PARTICIPANTS: A total of 1411 patients. INTERVENTION: Primary enucleation with or without adjuvant chemotherapy or radiotherapy. MAIN OUTCOME MEASURES: Orbital tumor recurrence, tumor-related metastasis, and tumor-related death. RESULTS: According to the 8th edition AJCC pathological classification, 645 eyes (46%) belonged to pathological T (pT)1, 164 (11%) to pT2, 493 (35%) to pT3, and 109 (8%) to pT4 categories. At a mean follow-up of 38 months (median, 35 months; < 1-149 months), orbital tumor recurrence was seen in 8 (1%), 5 (3%), 22 (4%), and 25 (23%) of pT1, pT2, pT3, and pT4 (P < 0.001) categories, respectively; tumor-related metastasis was seen in 7 (1%), 5 (3%), 40 (8%), and 46 (43%) of pT1, pT2, pT3, and pT4 (P < 0.001) categories, respectively; tumor-related death was seen in 12 (2%), 7 (4%), 64 (13%), and 64 (59%) of pT1, pT2, pT3, and pT4 (P < 0.001) categories, respectively. Multivariate Cox proportional hazards analysis of outcomes revealed pT category and adjuvant therapy as independent predictors of outcomes. Categories pT3b (P = 0.005), pT3c (P < 0.001), pT3d (P < 0.001), and pT4 (P < 0.001) had a greater hazard for orbital recurrence; categories pT2a (P = 0.015), pT3a (P < 0.001), pT3b (P < 0.001), pT3c (P < 0.001), pT3d (P < 0.001), and pT4 (P < 0.001) had a greater hazard for tumor-related metastasis; and categories pT2a (P = 0.068), pT2b (P = 0.004), pT3a (P < 0.001), pT3b (P < 0.001), pT3c (P < 0.001), pT3d (P < 0.001), and pT4 (P < 0.001) had a greater hazard for tumor-related death when compared with the pT1 category. Patients who did not receive adjuvant therapy had greater hazards of orbital tumor recurrence in categories pT3b (P = 0.005), pT3c (P = 0.003), and pT4 (P = 0.002); greater hazards of tumor-related metastasis in categories pT3a (P = 0.001), pT3b (P = 0.01), pT3c (P = 0.001), and pT4 (P = 0.007); and tumor-related death in categories pT3a (P < 0.001), pT3b (P = 0.009), pT3c (P = 0.018), and pT4 (P < 0.001) when compared with those who received adjuvant therapy. CONCLUSIONS: The 8th edition AJCC pathological classification predicts outcomes in patients undergoing primary enucleation for RB, and adjuvant therapy is associated with a lower risk of orbital recurrence, tumor-related metastasis, and tumor-related death in the pT3 and pT4 categories. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Vempuluru VS, Shields CL, Berry JL, et al. Retinoblastoma Outcomes Based on the 8th Edition American Joint Committee on Cancer Pathological Classification in 1411 Patients. Ophthalmology. 2024. PMID: 39245078. doi:10.1016/j.ophtha.2024.08.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。